



Celgene Corporation  
Investor Relations Department  
86 Morris Avenue  
Summit, NJ 07901  
United States

[Visit IR website](#)   
[Sign-up for e-mail alerts](#)

#### NASDAQ: CELG

Last Trade:	90.88
Trade Time:	4:00 PM ET Aug 20, 2018
Change:	0.51 (0.564%)
Day Range	89.83 - 91.28
52-Week Range	74.13 - 147.17
Volume	4,694,106

Stock information is provided by eSignal,  
stock charts provided by EDGAR Online.  
Stock data is delayed approximately 20  
minutes.

## Company Profile

Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of innovative therapies for the treatment of cancer and immune-inflammatory related diseases. Our portfolio of commercial products include REVLIMID<sup>®</sup>, VIDAZA<sup>®</sup>, THALOMID<sup>®</sup>, POMALYST<sup>®</sup>/IMNOVID<sup>®</sup>, ABRAXANE<sup>®</sup>, OTEZLA<sup>®</sup>, ISTODAX<sup>®</sup> and IDHIFA<sup>®</sup>. The drug candidates in our pipeline are at various stages of preclinical and clinical development. These cand... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

Jul 26, 2018

[Celgene Reports Second Quarter 2018 Operating and Financial Results](#)

Jul 23, 2018

[Celgene Announces Phase III 'AUGMENT' Study of REVLIMID<sup>®</sup> in Combination with Rituximab \(R<sup>2</sup>\) for the Treatment of Patients with Relapsed/Refractory Indolent Lymphoma Met Primary Endpoint](#)

Jul 10, 2018

[Anti-PD-L1 Immunotherapy Plus ABRAXANE<sup>®</sup> Significantly Reduced the Risk of Disease Worsening or Death in Patients with Metastatic or Locally Advanced Triple Negative Breast Cancer in Phase III IMpassion130 Study](#)

Jul 9, 2018

[Celgene and Acceleron Announce Luspatercept Achieved Primary and All Key Secondary Endpoints in Phase III 'BELIEVE' Study in Adults with Transfusion-Dependent Beta-Thalassemia](#)

Jul 2, 2018

[Celgene Corporation to Announce Second Quarter 2018 Results on July 26, 2018](#)

## Financials [\[ View all \]](#)

Feb 7, 2018

[Annual Report \(10-K\)](#)

Apr 30, 2018

[Proxy Statement \(DEF 14A\)](#)

Jul 26, 2018

[Quarterly Report \(10-Q\)](#)

May 4, 2018

[Quarterly Report \(10-Q\)](#)

Oct 26, 2017

[Quarterly Report \(10-Q\)](#)